<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00786474</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00017344</org_study_id>
    <secondary_id>1U01HL086755-01A1</secondary_id>
    <secondary_id>1U01HL087229</secondary_id>
    <nct_id>NCT00786474</nct_id>
  </id_info>
  <brief_title>Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)</brief_title>
  <official_title>Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood thinners, such as warfarin, prevent blood clots from forming, thereby reducing the risk
      of a stroke or heart attack. When people undergo surgery or certain procedures, they must
      stop using warfarin to prevent too much bleeding during and after the surgery or procedure.
      Some doctors prescribe a different blood thinner, one that works more quickly and wears off
      more quickly, to bridge the gap between starting and stopping warfarin. However, this
      short-term treatment is expensive, may increase the risk of bleeding, and has not been proven
      effective. This study will determine whether a bridging blood thinner called dalteparin is
      helpful or harmful for people with atrial fibrillation who stop taking warfarin in
      preparation for surgery or a procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 2 million people in North America take the anticoagulant warfarin to prevent
      stroke, heart attack, and other events related to blood clots. Warfarin needs to be stopped
      before a person undergoes surgery or certain procedures because it can cause dangerous
      amounts of bleeding during and after surgery. Some doctors give a low molecular weight
      heparin (LMWH) to patients during the 2-week period when participants are without the effects
      of warfarin. The LMWH has the same effect as warfarin, but it acts and then leaves the system
      more quickly than warfarin. However, the LMWH is expensive, may increase the risk of
      bleeding, and has not been proven effective. This study will determine the safety and
      efficacy of an LMWH in adults with atrial fibrillation who stop warfarin in preparation for
      surgery.

      Participation in this study will last between 36 and 67 days. Participation will involve nine
      points of contact with researchers, at least two of which will be in-person visits at the
      research clinic. The others will be conducted by phone. All points of contact will include
      assessments on possible bleeding and any new symptoms. The first two of these points of
      contact, will take place at the signing of the informed consent, which will involve a
      screening of medical records and random assignment of participants to receive either the LMWH
      dalteparin or placebo. Participants will self-administer a subcutaneous injection of their
      assigned treatment twice a day for 3 days before the surgery or procedure and for 6 days
      after. During the course of the study, when participants visit their primary physicians for
      regularly scheduled appointments, it will be recommended that they undergo two international
      normalized ratio (INR) tests of blood clotting ability between day 2 and 10 after the surgery
      or procedure. The remaining seven points of contact will occur sometime between the day
      before surgery and 37 days after surgery. One of the in-person visits will occur within the
      first week after surgery and will include assessments on possible bleeding, any new symptoms,
      and INR results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Arterial Thromboembolic Events</measure>
    <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
    <description>The events are defined as arterial thromboembolism: stokes, transient ischemic attack and systemic embolism events were independently and blindly adjudicated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
    <description>Major bleeding is defined as symptomatic bleeding associated with transfusion of more than two units of packed red blood cells or whole blood, or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism</measure>
    <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Minor Bleeding</measure>
    <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
    <description>Minor bleeding is defined as symptomatic or clinically-overt bleeding that does not satisfy the criteria for major bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1884</enrollment>
  <condition>Arterial Thromboembolic Events</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalteparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
    <arm_group_label>Dalteparin</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving warfarin therapy for at least 3 months, administered to achieve an
             international normalized ratio (INR) range of 2.0 to 3.0

          -  Requiring temporary interruption of warfarin for pre-specified elective procedure or
             surgery

          -  Presence of one of the following conditions:

               1. Chronic (permanent or paroxysmal) nonvalvular atrial fibrillation, confirmed by
                  at least one prior electrocardiography recording or pacemaker or acid citrate
                  dextrose (ACD) interrogation

               2. Chronic (permanent or paroxysmal) valvular atrial fibrillation with evidence of
                  mitral valvular heart disease, confirmed by the same criteria as nonvalvular
                  atrial fibrillation

          -  Presence of at least one of the following major stroke risk factors:

               1. Older than 75 years of age

               2. Hypertension

               3. Diabetes mellitus

               4. Congestive heart failure or left ventricular dysfunction

               5. Previous ischemic stroke, systemic embolism, or transient ischemic attack (TIA)

        Exclusion Criteria:

          -  Any mechanical prosthetic heart valve

          -  Stroke (ischemic or hemorrhagic), systemic embolism, or TIA within the past 12 weeks

          -  Venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) within past 12
             weeks

          -  Major bleeding within the past 6 weeks

          -  Severe renal insufficiency, measured through a calculated creatinine clearance of less
             than 30 mL/min

          -  Thrombocytopenia

          -  Life expectancy less than 1 month

          -  Condition that impairs compliance with trial protocol, such as cognitive impairment,
             an uncontrolled psychiatric condition, or geographic inaccessibility

          -  Pregnancy

          -  Allergy to heparin or history of heparin-induced thrombocytopenia

          -  Having one of the following surgeries or procedures during warfarin interruption:

               1. Cardiac surgery, such as coronary artery bypass or heart valve replacement

               2. Neurosurgery that is intracranial or intraspinal, such as tumor resection or
                  aneurysm repair

               3. High-risk non-surgical procedures, such as brain biopsy

          -  Other surgical or non-surgical procedure that, at the discretion of the surgeon,
             precludes administration of therapeutic-dose low molecular weight heparin (LMWH) at
             any time in the post-procedure period

          -  More than one surgery planned during the trial period

          -  Prior participation in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L. Ortel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Hasselblad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2008</study_first_posted>
  <results_first_submitted>January 6, 2016</results_first_submitted>
  <results_first_submitted_qc>February 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2016</results_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bridging Anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>6585 subjects were screened. 4701 were excluded, 1884 subjects enrolled and underwent randomization.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
        </group>
        <group group_id="P2">
          <title>Dalteparin</title>
          <description>Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="950"/>
                <participants group_id="P2" count="934"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="913"/>
                <participants group_id="P2" count="891"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
        </group>
        <group group_id="B2">
          <title>Dalteparin</title>
          <description>Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="950"/>
            <count group_id="B2" value="934"/>
            <count group_id="B3" value="1884"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.8" spread="8.74"/>
                    <measurement group_id="B2" value="71.6" spread="8.88"/>
                    <measurement group_id="B3" value="71.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="696"/>
                    <measurement group_id="B2" value="686"/>
                    <measurement group_id="B3" value="1382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="860"/>
                    <measurement group_id="B2" value="849"/>
                    <measurement group_id="B3" value="1709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonwhite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Arterial Thromboembolic Events</title>
        <description>The events are defined as arterial thromboembolism: stokes, transient ischemic attack and systemic embolism events were independently and blindly adjudicated</description>
        <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
        <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Arterial Thromboembolic Events</title>
          <description>The events are defined as arterial thromboembolism: stokes, transient ischemic attack and systemic embolism events were independently and blindly adjudicated</description>
          <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.</population>
          <units>Arterial thromboembolic events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="895"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient Ischemic Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Bleeding</title>
        <description>Major bleeding is defined as symptomatic bleeding associated with transfusion of more than two units of packed red blood cells or whole blood, or death</description>
        <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
        <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <description>Major bleeding is defined as symptomatic bleeding associated with transfusion of more than two units of packed red blood cells or whole blood, or death</description>
          <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="895"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism</title>
        <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
        <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Death, Acute Myocardial Infarction, Deep Vein Thrombosis, or Pulmonary Embolism</title>
          <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="895"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deep-vein thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Minor Bleeding</title>
        <description>Minor bleeding is defined as symptomatic or clinically-overt bleeding that does not satisfy the criteria for major bleeding</description>
        <time_frame>from subject signing of the consent until completed the study (Day -30 to Day +37)</time_frame>
        <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
          </group>
          <group group_id="O2">
            <title>Dalteparin</title>
            <description>Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Minor Bleeding</title>
          <description>Minor bleeding is defined as symptomatic or clinically-overt bleeding that does not satisfy the criteria for major bleeding</description>
          <population>Of the 1,884 subjects enrolled in the trial, 71 discontinued participation and did not provide outcome data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="895"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from subject signing of the consent until completed the study from Day -30 to Day +37</time_frame>
      <desc>Study only collected and reported serious adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: Normal saline solution, dosage determined by weight, self-administered by patient twice a day</description>
        </group>
        <group group_id="E2">
          <title>Dalteparin</title>
          <description>Dalteparin: Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hypocoagulable State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Gastric Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Pancreatic Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Gallbladder Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Perirectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Incision Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Splenic Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Traumatic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Urinary Retention Postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Vaginal Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Culture Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Qt Prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hyperosmolar State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Soft Tissue Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma Of Colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Endometrial Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hepatic Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Intraductal Proliferative Breast Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Oesophageal Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Embolic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Urethral Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="934"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="934"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Ortel, MD, PhD, Principal Investigator</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-5350 ext 3</phone>
      <email>thomas.ortel@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

